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CASE

REPORT

A case of eosinophilic annular
erythema as a presenting sign for
autoimmune hepatitis
Olabola Awosika, MD, MS,a Kristin Totoraitis, BS,b Misty Eleryan, MD,a Monica Rengifo-Pardo, MD,a and
Alison Ehrlich, MD, MHSa,c
Washington, DC, and Rochester, Minnesota
Key words: autoimmune hepatitis; eosinophilic annular erythema; figurate erythema; gyrate erythema;
hypersensitivity reaction; Wells syndrome.

INTRODUCTION
Eosinophilic annular erythema (EAE) is a relatively new entity, clinically presenting as a figurate
erythema. The cause of EAE remains obscure, but it
has been associated with several chronic conditions
and malignancies. We describe an unusual case of
EAE developing before the onset of autoimmune
hepatitis.

REPORT OF A CASE
A 22-year-old man with history of acne was
referred to our dermatology department for possible
patch testing and evaluation of his widespread rash.
Three months before referral, the patient had an
eruption of well-demarcated plaques on his scalp,
face, neck, and extremities, associated with pruritus.
The patient’s eruption was refractory to topical
corticosteroids (desoximetasone, clobetasol, and
triamcinolone). The patient denied similar eruption
in family members or close contacts. Additional
medical history, including new medications, changes
in personal products, and new sexual contacts, was
noncontributory, and detailed review of systems was
found to be negative.
Physical examination found annular erythematous plaques with central clearing on the trunk and
extremities, including the palms of both hands
(Fig 1). The face, scalp, and inguinal area were
spared. Results of laboratory tests, which included
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Abbreviation used:
EAE:

eosinophilic annular erythema

complete blood count, complete metabolic panel,
rapid plasma reagin, hepatitis panel, HIV antibody,
herpes simplex virus antibody, and Lyme titers, were
normal, with the exception of eosinophilia (13%).
Biopsies of the back and abdomen performed by
his outside dermatologist found subacute spongiotic
dermatitis with parakeratosis, preservation of the
dermoepidermal junction, and superficial to midperivascular lymphohistiocytic cell infiltrate (Fig 2,
A-C ). At the level of the dermis, interstitial mucin
deposition and scattered eosinophils were visible,
with notable absence of flame figures. The diagnosis
of eosinophilic annular erythema was favored given
his clinical presentation and pathology results.
The patient had considerable improvement on
oral prednisone, but his condition flared when this
medication was tapered. A trial of hydroxychloroquine, 200 mg twice daily, was discontinued after
4 weeks of therapy because of lack of effective
response. Methotrexate, 10 mg weekly, was found to
be efficacious. Unfortunately, leukocytosis and
worsening eosinophilia developed (increasing
from 8.1 3 103/L to 23.2 3 103/L and 42% to
65%, respectively), leading to discontinuation of
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Fig 1. Eosinophilic annular erythema (EAE). Multiple
erythematous annular plaques with central clearing
involving the neck, trunk, and extremities.

methotrexate after 2 weeks of therapy. While on
methotrexate, the patient had blisters on his feet,
bilateral ankle swelling, and stiff knees. He was
referred to the oncology department, given reports
of malignancy in the literature associated with
eosinophilic annular erythema and his leukocytosis.
Two weeks after cessation of methotrexate, the
patient’s leukocytosis resolved and his eosinophilia
declined to 20%.
Over the next 10 weeks, the patient was treated
with fluocinonide cream and mycophenolate mofetil, 500 mg twice daily decreased to once daily
(because of increased aspartate aminotransferase,
alanine aminotransferase, and alkaline phosphatase
to 107 IU/L, 91 IU/L, and 199 IU/L, respectively).
Despite moderate improvement in his skin, the
patient was advised to discontinue mycophenolate
mofetil and was referred to the gastroenterology
department for increasing elevation of liver enzymes
(aspartate aminotransferase, 212 IU/L; alanine
aminotransferase, 145 IU/L; and alkaline phosphatase, 207 IU/L). Drug-induced hepatitis was
excluded as a causative factor because of continued
elevation of liver enzymes for 2 months after
discontinuation
of
mycophenolate
mofetil.
Investigation found positive smooth muscle antibody, elevation of serum IgG (2037 mg/dL), and a
liver biopsy showing chronic nonspecific hepatitis
consistent with a diagnosis of autoimmune hepatitis.
The patient was started on prednisone, 60 mg once
daily, and is now having resolution of his rash with
mild postinflammatory hyperpigmentation.

DISCUSSION
EAE is a chronic and recurrent skin disease.
Clinically, it presents as urticarial, annular papules
and plaques on the trunk and extremities.1,2 The

Fig 2. A, Histopathology shows marked alterations in the
epidermis (spongiosis and parakeratosis) and superficial
and deep inflammatory infiltrate within the dermis. B and
C, Perivascular and interstitial infiltrate composed of
eosinophils and lymphocytes with mucin noted between
dermal collagen bundles. (A to C, Hematoxylin-eosin
stain; original magnifications: A, 34; B, 320; and C, 340.)

lesions are typically asymptomatic or mildly pruritic.3 Over time, these lesions can adopt an annular
or polycyclic pattern with central clearing.4 During
resolution, transient pigment changes may be
observed, but no atrophy or scarring occurs.4
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Similar to most figurate erythemas, EAE is of unknown etiology. However, EAE is hypothesized to
be the result of a hypersensitivity reaction to an
unknown antigen.5 EAE can be differentiated from
other figurate erythemas by clinical history
(excluding tick exposure), absence of scale, presence of eosinophils in the dermis, and negative Lyme
titers, as seen in our patient.2,6
It is debated whether EAE is a subset of Wells
syndrome or if it is a distinct entity in itself. Wells
syndrome, also known as eosinophilic cellulitis, is an
inflammatory dermatitis that has a wide range of
clinical presentations. However, Wells syndrome
typically presents as acute erythematous plaques
usually resolving with hyperpigmentation and residual atrophy, as opposed to EAE, which resolves with
no sequlae.2 Wells syndrome can occur in patients of
any age, and lesions rarely affect the face.7 The
histopathologic findings of Wells syndrome include
dermal edema, eosinophils, and ‘‘flame figures’’
formed by eosinophilic granules coating collagen.8
In contrast, EAE is characterized by superficial and
deep perivascular lymphocytic infiltrate with
numerous eosinophils.2 Although both conditions
have tissue eosinophilia, EAE is also distinguished
from Wells syndrome by the absence of flame figures
and diffuse inflammatory infiltrate on histopathology
as seen in our case.2,5 However, multiple cases of
EAE have been reported with the histopathologic
findings of flame figures.6,9,10 This variation in
findings is thought to be because of the timing of
when the biopsy specimens are taken, with earlier
EAE lesions being devoid of flame figures and welldeveloped EAE lesions containing them.5,6
Although EAE can be self-limited, it often runs a
chronic relapsing and remitting course with variable
response to treatment.3 Both antimalarials and systemic steroids are reported to clear the lesions.4-6
However, early relapse after discontinuation of these
treatments is common.4,6,9 Additional treatments
reported to have some success include dapsone,
indomethacin, nicotinamide, and ultraviolet B phototherapy.3,4,9,11 Of note, El-Khalawany et al6
observed that treatment of associated diseases
(including chronic gastritis, diabetes mellitus,
chronic hepatitis C virus infection, and chronic
kidney disease) increased the time of remission
and decreased the rate of relapse in their EAE
patients treated with prednisone alone or in conjunction with cyclosporine or hydroxychloroquine.
Multiple chronic conditions are reported to
have a possible association with EAE, including
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autoimmune thyroid disease, borreliosis, chronic
gastritis caused by Helicobacter pylori infection,
diabetes mellitus, hepatitis C infection, chronic kidney disease, thymoma, and autoimmune pancreatitis.1,6,11 Coexisting malignancy and EAE have also
been reported, specifically, clear cell renal carcinoma and metastatic prostate cancer.9,10 To our
knowledge, there are no reports of EAE in association with autoimmune hepatitis. Additionally, this
case shows the unique development of hepatic
disease 7 months after onset of EAE. Furthermore,
the correlation between adequate treatment of the
patient’s autoimmune hepatitis and resolution of his
rash suggests the importance for awareness of EAE as
a presenting sign for evolving systemic disease in the
absence of a malignancy or chronic condition at
initial presentation.
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